Yahoo Web Search

Search results

1. • Why Merck & Co Inc (NYSE: MRK) Is A Stock Not To Be Discarded In 2024 – Marketing Sentinel

     Marketing Sentinel· 3 days ago

     In today’s recent session, 2.33 million shares of the Merck & Co Inc (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share ...

2. • 

     Earnings call: Merck sees organic growth despite market challenges By Investing.com

     Investing.com· 15 hours ago

     Merck & Co., Inc. (MRK) reported its first-quarter results for 2024, revealing a slight decline in...

3. • 

     Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations

     FierceBiotech· 3 days ago

     Merck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...

4. • 

     Top Stock Reports for Broadcom, Merck & Airbnb

     Zacks via Yahoo Finance· 15 hours ago

     Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).

5. • 

     Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential

     FierceBiotech· 17 hours ago

     What a time to be launching a new biotech focused on inflammation and immunology. Uniquity Bio is...

6. • 

     ...Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment - ...

     Benzinga· 3 days ago

     Monday, Merck & Co Inc MRK announced the discontinuation of the vibostolimab and pembrolizumab...

7. • 

     Merck cancels trial of melanoma treatment due to immune-mediated adverse events

     Clinical Trials Arena via Yahoo Finance· 2 days ago

     US pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a...

8. • 

     Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years

     Simply Wall St. via Yahoo Finance· 6 days ago

     By buying an index fund, investors can approximate the average market return. But if you pick the...

9. • Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study

     Morningstar· 3 days ago

     Merck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the ...

10. • 

      Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

      Zacks via Yahoo Finance· 2 days ago

      With Merck’s growth largely depending on Keytruda, the recent pipeline setbacks do not bode well for...